搜索
MeiraGTx Holdings PLC
MGTX添加自选
9.400USD
-0.550-5.53%
收盘 05/15, 16:00（美东）报价延迟15分钟
762.54M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-5.53%
5天
-4.28%
1月
-0.84%
6月
+14.77%
今年开始到现在
+18.24%
1年
+88.38%
TradingKey MeiraGTx Holdings PLC股票评分
单位: USD 更新时间: 2026-05-15操作建议
MeiraGTx Holdings PLC当前公司基本面数据相对谨慎，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名126/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价25.71。中期看，股价处于上升通道。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
MeiraGTx Holdings PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
MeiraGTx Holdings PLC亮点
亮点风险
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
业绩高增长
公司营业收入稳步增长，连续3年增长480.66%
业绩增长期
公司处于发展阶段，最新年度总收入81.39M美元
利润高增长
公司净利润处于行业前列，最新年度总收入81.39M美元
估值低估
公司最新PE估值-6.33，处于3年历史低位
机构减仓
最新机构持股53.71M股，环比减少3.14%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值71.65K
活跃度增加
近期活跃度增加，过去20天平均换手率1.05
分析师目标
根据
8
位分析师
买入
评级
28.000
目标均价
+181.41%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
MeiraGTx Holdings PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
MeiraGTx Holdings PLC简介
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
公司代码MGTX
公司MeiraGTx Holdings PLC
CEOForbes (Alexandria)
网址https://meiragtx.com/
相关品种
